Alembic Pharmaceuticals has informed the exchange that the Company's joint venture, Aleor Dermaceuticals, has received US Food and Drug Administration (USFDA) Final Approval for Tavaborole Topical Solution, 5%. The company has enclosed its press release on 22 October 2020.
The above information is a part of company’s filings submitted to BSE.